Uso hospitalario de inhibidores de la bomba de protones y antimicrobianos, y su asociación con el riesgo de infección por Clostridioides difficile: un enfoque de Farmacovigilancia
Latin american journal of clinical sciences and medical technology · 24.07.2026 · 8 (1) · 86-99
DOI: 10.34141/ljcs3532768 ↗Kurz gefasst
Fachartikel in der Zeitschrift Latin american journal of clinical sciences and medical technology, erschienen am 24.07.2026. Verfasst von Yesenia Sánchez Lugo. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Clostridioides difficile infection (CDI) is the leading cause of healthcare - associated diarrhea and is strongly linked to pharmacological exposure, particularly antimicrobials and proton pump inhibitors (PPIs).
Objective
To evaluate the association between antimicrobial and PPI use and the risk of CDI in hospitalized patients. Materials and Methods. A retrospective observational analytical case - control study was conducted. A total of 60 hospitalized patients were included (30 cases with confirmed CDI and 30 controls without infection). Demographic, clinical, and pharmacological variables were analyzed. Associations between exposure factors and infection were estimated using crude odds ratios (OR) with 95 % confidence intervals (95 % CIs).
Results
Patients with CDI were older (52.61 ± 18.81 vs. 39.62 ± 16.98 years; p = 0.0036) and received more prescribed antibiotics (4.07 ± 2.29 vs. 2.00 ± 2.42; p = 0.0012). Polyantibiotic therapy (≥3 antibiotics) was significantly associated with CDI (OR: 6.57; 95 % CI: 2.11-20.48; p = 0.0016). Prolonged PPI use (≥7 days) was also significantly associated (OR: 4.57; 95 % CI: 1.45-14.39; p = 0.015). Carbapenem (56.7 % vs. 26.7 %; p = 0.036) and clindamycin use (26.7 % vs. 6.7 %; p = 0.034) were more frequent among cases, although these associations were not statistically significant in risk estimation.
Conclusions
Polyantibiotic therapy and prolonged PPI use were significantly associated with CDI. Antimicrobial exposure burden appears to be the main pharmacological determinant, while PPIs may act as a contributing factor. Incorporating CDI into pharmacovigilance systems may improve prescribing practices and enhance patient safety in hospital settings.
Zitieren
APA
Lugo, Y. S. (2026). Uso hospitalario de inhibidores de la bomba de protones y antimicrobianos, y su asociación con el riesgo de infección por Clostridioides difficile: un enfoque de Farmacovigilancia. Latin american journal of clinical sciences and medical technology, 8(1), 86-99. https://doi.org/10.34141/ljcs3532768
Vancouver
Lugo YS. Uso hospitalario de inhibidores de la bomba de protones y antimicrobianos, y su asociación con el riesgo de infección por Clostridioides difficile: un enfoque de Farmacovigilancia. Latin american journal of clinical sciences and medical technology. 2026;8(1):86-99. doi:10.34141/ljcs3532768
BibTeX
@article{Lugo2026,
author = {Lugo, Yesenia Sánchez},
title = {Uso hospitalario de inhibidores de la bomba de protones y antimicrobianos, y su asociación con el riesgo de infección por Clostridioides difficile: un enfoque de Farmacovigilancia},
journal = {Latin american journal of clinical sciences and medical technology},
year = {2026},
volume = {8},
number = {1},
pages = {86--99},
doi = {10.34141/ljcs3532768}
}
EUVIMED